GFM
RIGL icon

GF Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

GF Fund Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Buy
407
+51
+14% +$1.71K ﹤0.01% 552
2025
Q4 		$15.2K Sell
356
-28
-7% -$1.05K ﹤0.01% 537
2025
Q3 		$10.9K Sell
384
-67
-15% -$2K ﹤0.01% 548
2025
Q2 		$8.45K Hold
451
– – ﹤0.01% 584
2025
Q1 		$8.11K Buy
451
+81
+22% +$1.64K ﹤0.01% 585
2024
Q4 		$6.22K Buy
+370
New +$7.1K ﹤0.01% 600

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GF Fund Management's RIGL Position: Q1 2026 in Review

GF Fund Management increased its Rigel Pharmaceuticals (RIGL) stake by 14% in Q1 2026, buying an estimated $1.71K and bringing the position to 407 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #552.

GF Fund Management first reported a position in RIGL in Q4 2024 and has held it in 6 quarters since. The position peaked at $15.2K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • GF Fund Management held 407 shares of Rigel Pharmaceuticals worth $11K as of Q1 2026.
  • GF Fund Management bought 51 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.71K.
  • Rigel Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #552 holding.
  • GF Fund Management first reported a position in Rigel Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Rigel Pharmaceuticals position peaked at $15.2K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.